Meta-DOB
| Clinical data | |
|---|---|
| Other names | 5-Bromo-2,4-dimethoxyamphetamine; 2,4-Dimethoxy-5-bromoamphetamine; 5-Bromo-TMA-2 |
| Routes of administration | Oral[1] |
| Drug class | Psychoactive drug |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | 5–6 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H16BrNO2 |
| Molar mass | 274.158 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Meta-DOB, also known as 5-bromo-2,4-dimethoxyamphetamine, is a psychoactive drug of the phenethylamine and amphetamine families related to the psychedelic drug DOB.[1] It is a positional isomer of DOB in which the bromine atom at the 4 position and the methoxy group at the 5 position have been interchanged.[1]
In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists meta-DOB's dose range as 50 to 100 mg orally and its duration as 5 to 6 hours.[1] The effects of meta-DOB have been reported to include MDA-like effects, vague uneasiness, possible threshold psychedelic effects, anxiety, paranoid fantasies, and toxic signs such as flushing, palpitations, and occasional nausea, vomiting, and diarrhea.[1][2] It has been said that any possible psychedelic effects of meta-DOB seem to have been blurred by its more obvious toxic effects.[1]
The chemical synthesis of meta-DOB has been described.[1] A notable analogue of meta-DOB is meta-DOT.[1]
Meta-DOB was first described in the scientific literature by Silvia Sepúlveda and colleagues by 1972.[2] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1]
See also
References
- ^ a b c d e f g h i j Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
- ^ a b Sepúlveda S, Valenzuela R, Cassels BK (April 1972). "Potential psychotomimetics. New bromoalkoxyamphetamines". J Med Chem. 15 (4): 413–415. doi:10.1021/jm00274a022. PMID 5019563.